“
TL;DR
The central result is that current control programs targeting infection prevalence may not fully address the future burden of these delayed pathologies.
Philosophical Transactions of the Royal Society B: Biological Sciences · 3 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The central result is that current control programs targeting infection prevalence may not fully address the future burden of these delayed pathologies.
It synthesizes evidence showing that for many NTDs, pathology arises from cumulative exposure or repeated infection over many years, analogous to a dose-response relationship. They highlight that interventions reducing infection prevalence may not immediately stop the progression of established disease, as seen in the slow development of trachomatous scarring or liver fibrosis. Limitations include the difficulty in quantifying host-specific factors and the lack of long-term longitudinal data linking exposure histories to outcomes. The implication is that morbidity models must incorporate these complex, delayed pathways to accurately project future disease burden and inform public health strategies.